{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:57:27Z","timestamp":1784894247492,"version":"3.55.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.vaccine.2017.04.062","type":"journal-article","created":{"date-parts":[[2017,5,5]],"date-time":"2017-05-05T14:32:47Z","timestamp":1493994767000},"page":"3239-3248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["A prime-boost immunization regimen based on a simian adenovirus 36 vectored multi-stage malaria vaccine induces protective immunity in mice"],"prefix":"10.1016","volume":"35","author":[{"given":"Jairo A.","family":"Fonseca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica N.","family":"McCaffery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Kashentseva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balwan","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor P.","family":"Dmitriev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Curiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.04.062_b0005","series-title":"World malaria report 2016","author":"World Health Organization","year":"2016"},{"key":"10.1016\/j.vaccine.2017.04.062_b0010","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1146\/annurev-immunol-032713-120220","article-title":"Malaria immunity in man and mosquito: insights into unsolved mysteries of a deadly infectious disease","volume":"32","author":"Crompton","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2017.04.062_b0015","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1462-5822.2001.00097.x","article-title":"Gliding motility and cell invasion by Apicomplexa: insights from the Plasmodium sporozoite","volume":"3","author":"Menard","year":"2001","journal-title":"Cell Microbiol"},{"key":"10.1016\/j.vaccine.2017.04.062_b0020","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0092-8674(00)80511-5","article-title":"TRAP is necessary for gliding motility and infectivity of plasmodium sporozoites","volume":"90","author":"Sultan","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2017.04.062_b0025","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/1475-2875-7-142","article-title":"Cohort study of the association of antibody levels to AMA1, MSP119, MSP3 and GLURP with protection from clinical malaria in Ghanaian children","volume":"7","author":"Dodoo","year":"2008","journal-title":"Malaria J"},{"key":"10.1016\/j.vaccine.2017.04.062_b0030","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1056\/NEJMoa1102287","article-title":"First results of phase 3 trial of RTS, S\/AS01 malaria vaccine in African children","volume":"365","author":"Agnandji","year":"2011","journal-title":"New Engl J Med"},{"key":"10.1016\/j.vaccine.2017.04.062_b0035","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1473-3099(13)70005-7","article-title":"Efficacy of RTS, S malaria vaccines: individual-participant pooled analysis of phase 2 data","volume":"13","author":"Bejon","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.062_b0040","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/1475-2875-8-312","article-title":"Immunological mechanisms underlying protection mediated by RTS, S: a review of the available data","volume":"8","author":"Moorthy","year":"2009","journal-title":"Malaria J"},{"key":"10.1016\/j.vaccine.2017.04.062_b0045","first-page":"41","article-title":"Malaria and the liver: immunological hide-and-seek or subversion of immunity from within?","volume":"6","author":"Bertolino","year":"2015","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2017.04.062_b0050","doi-asserted-by":"crossref","first-page":"e61395","DOI":"10.1371\/journal.pone.0061395","article-title":"The relationship between RTS, S vaccine-induced antibodies, CD4(+) T cell responses and protection against Plasmodium falciparum infection","volume":"8","author":"White","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.04.062_b0055","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1128\/IAI.01063-15","article-title":"Tailoring a combination preerythrocytic malaria vaccine","volume":"84","author":"Bauza","year":"2015","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.04.062_b0060","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.micinf.2008.10.009","article-title":"Recombinant peptide replicates immunogenicity of synthetic linear peptide chimera for use as pre-erythrocytic stage malaria vaccine","volume":"11","author":"Silva-Flannery","year":"2009","journal-title":"Microbes Infect\/Institut Pasteur"},{"key":"10.1016\/j.vaccine.2017.04.062_b0065","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1016\/j.vaccine.2010.01.019","article-title":"Genetic linkage of autologous T cell epitopes in a chimeric recombinant construct improves anti-parasite and anti-disease protective effect of a malaria vaccine candidate","volume":"28","author":"Singh","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.062_b0070","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1128\/IAI.05980-11","article-title":"A hybrid multistage protein vaccine induces protective immunity against murine malaria","volume":"80","author":"Singh","year":"2012","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.04.062_b0075","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.4049\/jimmunol.1501926","article-title":"A recombinant chimeric Ad5\/3 vector expressing a multistage plasmodium antigen induces protective immunity in mice using heterologous prime-boost immunization regimens","volume":"197","author":"Cabrera-Mora","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.04.062_b0080","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1099\/vir.0.81989-0","article-title":"Generation of an adenoviral vaccine vector based on simian adenovirus 21","volume":"87","author":"Roy","year":"2006","journal-title":"J General Virol"},{"key":"10.1016\/j.vaccine.2017.04.062_b0085","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/sj.gt.3300994","article-title":"Immune responses to adenovirus and adeno-associated virus in humans","volume":"6","author":"Chirmule","year":"1999","journal-title":"Gene Ther"},{"key":"10.1016\/j.vaccine.2017.04.062_b0090","doi-asserted-by":"crossref","first-page":"e101591","DOI":"10.1371\/journal.pone.0101591","article-title":"Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial","volume":"9","author":"Hayton","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.04.062_b0095","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/jgm.1530","article-title":"Creation of a panel of vectors based on ape adenovirus isolates","volume":"13","author":"Roy","year":"2011","journal-title":"J Gene Med"},{"key":"10.1016\/j.vaccine.2017.04.062_b0100","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.virol.2005.10.042","article-title":"Chimpanzee adenovirus vaccine protects against Zaire Ebola virus","volume":"346","author":"Kobinger","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2017.04.062_b0105","article-title":"Chimpanzee adenovirus vector ebola vaccine \u2013 preliminary report","author":"Ledgerwood","year":"2014","journal-title":"New Engl J Med"},{"key":"10.1016\/j.vaccine.2017.04.062_b0110","doi-asserted-by":"crossref","first-page":"115ra1","DOI":"10.1126\/scitranslmed.3003155","article-title":"Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man","volume":"4","author":"Barnes","year":"2012","journal-title":"Sci Translati Med"},{"key":"10.1016\/j.vaccine.2017.04.062_b0115","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1128\/IAI.00740-09","article-title":"Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses","volume":"78","author":"Reyes-Sandoval","year":"2010","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.04.062_b0120","doi-asserted-by":"crossref","first-page":"e31208","DOI":"10.1371\/journal.pone.0031208","article-title":"Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors","volume":"7","author":"Sheehy","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.04.062_b0125","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1038\/mt.2012.223","article-title":"ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans","volume":"20","author":"Sheehy","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2017.04.062_b0130","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1038\/mt.2011.176","article-title":"Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors","volume":"19","author":"Sheehy","year":"2011","journal-title":"Mol Ther: J Am Soc Gene Ther"},{"key":"10.1016\/j.vaccine.2017.04.062_b0140","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1128\/JVI.76.3.1100-1108.2002","article-title":"Artificial extension of the adenovirus fiber shaft inhibits infectivity in coxsackievirus and adenovirus receptor-positive cell lines","volume":"76","author":"Seki","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.04.062_b0145","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jmb.2009.03.016","article-title":"Targeting of adenovirus serotype 5 pseudotyped with short fiber from serotype 41 to c-erbB2-positive cells using bispecific single-chain diabody","volume":"388","author":"Kashentseva","year":"2009","journal-title":"J Mol Biol"},{"key":"10.1016\/j.vaccine.2017.04.062_b0150","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0042-6822(68)90121-9","article-title":"The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12","volume":"36","author":"Maizel","year":"1968","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2017.04.062_b0155","doi-asserted-by":"crossref","first-page":"e0154819","DOI":"10.1371\/journal.pone.0154819","article-title":"A plasmodium promiscuous T cell epitope delivered within the Ad5 hexon protein enhances the protective efficacy of a protein based malaria vaccine","volume":"11","author":"Fonseca","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.04.062_b0160","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.micinf.2005.04.020","article-title":"Chimeric epitopes delivered by polymeric synthetic linear peptides induce protective immunity to malaria","volume":"7","author":"Caro-Aguilar","year":"2005","journal-title":"Microbes Infect"},{"key":"10.1016\/j.vaccine.2017.04.062_b0165","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1128\/IAI.70.7.3479-3492.2002","article-title":"Plasmodium vivax promiscuous T-helper epitopes defined and evaluated as linear peptide chimera immunogens","volume":"70","author":"Caro-Aguilar","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.04.062_b0170","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0022-1759(95)00186-4","article-title":"The assessment of antibody affinity distribution by thiocyanate elution: a simple dose-response approach","volume":"187","author":"Ferreira","year":"1995","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2017.04.062_b0175","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/jcla.20172","article-title":"Improved method to calculate the antibody avidity index","volume":"21","author":"Perciani","year":"2007","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.vaccine.2017.04.062_b0180","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/ni.2180","article-title":"Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection","volume":"13","author":"Butler","year":"2012","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2017.04.062_b0185","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/cyto.a.21015","article-title":"SPICE: exploration and analysis of post-cytometric complex multivariate datasets","volume":"79","author":"Roederer","year":"2011","journal-title":"Cytometry A"},{"key":"10.1016\/j.vaccine.2017.04.062_b0190","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1126\/science.286.5444.1579","article-title":"Structural analysis of the mechanism of adenovirus binding to its human cellular receptor, CAR","volume":"286","author":"Bewley","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2017.04.062_b0195","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1099\/0022-1317-83-1-151","article-title":"Chimpanzee adenovirus CV-68 adapted as a gene delivery vector interacts with the coxsackievirus and adenovirus receptor","volume":"83","author":"Cohen","year":"2002","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2017.04.062_b0200","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1128\/IAI.01129-08","article-title":"Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness","volume":"77","author":"Stanisic","year":"2009","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.04.062_b0205","doi-asserted-by":"crossref","first-page":"e111020","DOI":"10.1371\/journal.pone.0111020","article-title":"IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice","volume":"9","author":"Schwenk","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.04.062_b0210","doi-asserted-by":"crossref","first-page":"6961","DOI":"10.4049\/jimmunol.171.12.6961","article-title":"Protective immunity induced with malaria vaccine, RTS, S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma","volume":"171","author":"Sun","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.04.062_b0215","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S0140-6736(02)09784-2","article-title":"Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum","volume":"360","author":"Pombo","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.04.062_b0220","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJMoa0805832","article-title":"Protection against a malaria challenge by sporozoite inoculation","volume":"361","author":"Roestenberg","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.04.062_b0225","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1038\/mt.2011.176","article-title":"Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors","volume":"19","author":"Sheehy","year":"2011","journal-title":"Mol Ther: J Am Soc Gene Ther"},{"key":"10.1016\/j.vaccine.2017.04.062_b0230","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1016\/j.vaccine.2012.05.048","article-title":"Malaria vaccines: focus on adenovirus based vectors","volume":"30","author":"Schuldt","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.062_b0235","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1182\/blood-2007-02-062117","article-title":"Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines","volume":"110","author":"Tatsis","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2017.04.062_b0240","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/CJI.0b013e31816a8910","article-title":"Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma","volume":"31","author":"Butterfield","year":"2008","journal-title":"J Immunother"},{"key":"10.1016\/j.vaccine.2017.04.062_b0245","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1089\/vim.2005.18.283","article-title":"Adenoviral vectors for mucosal vaccination against infectious diseases","volume":"18","author":"Santosuosso","year":"2005","journal-title":"Viral Immunol"},{"key":"10.1016\/j.vaccine.2017.04.062_b0250","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1128\/JVI.02696-06","article-title":"Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D","volume":"81","author":"Abbink","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.04.062_b0255","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1128\/CVI.00066-13","article-title":"Transgenic parasites stably expressing full-length Plasmodium falciparum circumsporozoite protein as a model for vaccine down-selection in mice using sterile protection as an endpoint","volume":"20","author":"Porter","year":"2013","journal-title":"Clin Vac Immunol"},{"key":"10.1016\/j.vaccine.2017.04.062_b0260","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1128\/JVI.02058-12","article-title":"Alternative serotype adenovirus vaccine vectors elicit memory T cells with enhanced anamnestic capacity compared to Ad5 vectors","volume":"87","author":"Penaloza-MacMaster","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.04.062_b0265","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1600-065X.2008.00671.x","article-title":"Protective CD8 T cells against Plasmodium liver stages: immunobiology of an 'unnatural' immune response","volume":"225","author":"Overstreet","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1016\/j.vaccine.2017.04.062_b0270","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/infdis\/jiu579","article-title":"Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals","volume":"211","author":"Hodgson","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.062_b0275","doi-asserted-by":"crossref","first-page":"7167","DOI":"10.1016\/j.vaccine.2010.08.068","article-title":"Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1","volume":"28","author":"Douglas","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.062_b0280","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/mt.2013.284","article-title":"Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens","volume":"22","author":"Antrobus","year":"2014","journal-title":"Mol Ther: J Am Soc Gene Ther"},{"key":"10.1016\/j.vaccine.2017.04.062_b0285","doi-asserted-by":"crossref","first-page":"8263","DOI":"10.1128\/JVI.77.15.8263-8271.2003","article-title":"Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity","volume":"77","author":"Vogels","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.04.062_b0290","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1016\/j.vaccine.2008.03.080","article-title":"Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-gamma and antibody responses in mice","volume":"26","author":"Shott","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.062_b0295","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1189\/jlb.0310137","article-title":"Interferon-gamma\u2013central mediator of protective immune responses against the pre-erythrocytic and blood stage of malaria","volume":"88","author":"McCall","year":"2010","journal-title":"J Leukoc Biol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17305546?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17305546?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T13:00:18Z","timestamp":1569243618000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17305546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":58,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0264410X17305546"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.04.062","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A prime-boost immunization regimen based on a simian adenovirus 36 vectored multi-stage malaria vaccine induces protective immunity in mice","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.04.062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}